Watch this free webinar to learn about the biggest challenges and opportunities facing the NGS oncology space.   You will hear from Darrell Green, a lecturer in RNA Biology at Norwich Medical School, Panna Sharma, CEO of Lantern Pharma, as well as Dr Stephane Budel and Dr Miguel Edwards, Founding Partner and Partner at DeciBio.  In […]

AI and machine learning (AI/ML) methods offer an alluring way to expedite the drug discovery process by delivering a large number of possible new candidates for any given therapeutic area. However, insight from medicinal chemists is still necessary to triage and prioritise the most promising molecules for synthesis, and progress these through the Design-Make-Test-Analyse (DMTA) […]

Cell and gene therapies are transforming the way diseases are treated. As research progresses it is hoped that cell and gene therapies will offer innovation for the future. In this on-demand webinar you will hear from CBO/CDO of Adthera Bio, Stuart Curbishley, Chief Executive Officer of Cell & Gene Therapy Catapult, Matthew Durdy, Founder and […]

CAR-T cell therapies are a promising approach for treating solid tumours. But identifying appropriate T-cell receptor (TCR) domains that exclusively target tumour antigens remains a challenge. Toxicity, tumour activation, and tumour persistence are significant challenges to using CAR-T cell therapies for solid tumours. In this webinar, Twist Bioscience’s CSO, Aaron Sato, will present several proof-of-concept […]

From human B cells to engineered antibodies, IgGenix is taking a novel approach towards breaking through the last frontier of immunology: allergies. By reengineering key antibodies in the allergic cascade, this biotech company is developing a first-in-class therapy for the millions of people whose daily lives are limited by food allergies and other severe allergic […]

Opto B Discovery on the Beacon optofluidic system is designed to enable rapid selection of lead candidates by function-forward screening of B cells in under one week. This presentation will introduce Berkeley Lights’ newest antibody discovery workflow, the Opto Memory B Discovery workflow, and share how customers are using the workflow to screen rabbit memory […]

Generation of a highly expressing, regulatory acceptable clonal cell line is the first key activity in the development of a biopharmaceutical. Cell line development is labour intensive, time consuming and costly and is subject to stringent regulations to ensure patient safety. All cell lines used to produce clinical batches of biopharmaceuticals are required to conform […]

Extensive manipulation, mechanical force, and labelling methods used to enrich cells activate transcriptional programs that mask molecular profiles truly significant to any underlying disease. The consequence is identification of drug targets that are not relevant to the biological process under study. Based on Nakhoda and Olszanski, 2022 (Addressing Recent Failures in Immuno-Oncology Trials to Guide […]

One critical bottleneck in Cell and Gene Therapy (CGT) manufacturing is the production of high-quality plasmid DNA (pDNA), a vital building block for mRNA-based vaccines, viral vector-based cell or gene therapies that require pDNA as a starting material. Building a robust supply of GMP-grade pDNA requires that quality be a focal point of the production […]

CRISPR-based knockouts are the gold-standard genetic perturbation method in target identification and validation. However, efficient CRISPR knockout editing and transfection for arrayed screening require specialised skills and infrastructure that your organisation may not have. What if you could receive ready-to-use CRISPR-edited cells without needing to handle, optimise, and transfect your CRISPR library?  In this on-demand […]

Neurodegenerative diseases are characterised by neuronal damage, degradation of the blood-brain barrier and failures in the normal repair mechanisms of the brain. Many of the most promising areas of drug development in this field target neuroinflammation and remyelination. In this on-demand webinar, presented by Dr Elise Malavasi, Principal Scientist at Concept Life Sciences, we use […]

Watch the webinar High resolution electron cryo-microscopy: From membrane proteins to diseases, supported by Thermo Fisher Scientific.  The webinar demonstrates how cryo-EM is impacting high resolution structure biology from membrane proteins to diseases including Alzheimer’s disease and cancer therapeutics by showing high-resolution structures of these proteins bound to inhibitors.  It is presented by Dr Abhay Kotecha, […]

Cryo-EM has been adopted into drug discovery workflows by the pharmaceutical and biotechnology industries having proved itself capable of delivering atomic resolution structures for key targets, including integral membrane proteins such as GPCRs and ion channels.   More recently, significant improvements in throughput have seen use of the technique expand quickly within the sector. Key to […]

Fragment-based drug discovery (FBDD) is a method used for finding hit compounds as one strategy of hit identification (hit ID) in the drug discovery process.   Introduction into Fragment Based Drug Discovery, hosted by DDW and supported by WuXi AppTec, is now available to watch online.  Fragments are small molecules with a low molecular weight (less […]

Tips and tricks on how to obtain and analyse high quality data from live cell, high throughput assays of signaling dynamics. Genetically encoded fluorescent biosensors enable continuous recording of cellular signaling in live cells. This breakthrough technology provides unprecedented, real-time measurements of signaling dynamics, which is emerging as a critical determinant of physiological function and […]

Charles River, Antibody Discovery group, has integrated computational immunology, antibody engineering and phage display technologies into its comprehensive antibody discovery platforms that rapidly deliver antibody hits or optimised variants with a range of affinities, cross-species coverage, and improved drug-like characteristics. Charles River uses label-free biosensors and other bioanalytical assays to support biochemical/biophysical characterisation of biotherapeutic […]